Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna
®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the year ended December 31, 2013, at the close of trading on Thursday, February 27, 2014. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. EST on Thursday, February 27.
Conference Call and Webcast Details
To listen to the conference call, dial in approximately ten minutes before the scheduled 4:30 P.M. time to (253) 237-1170 or toll free at (877) 372-0867. Please reference conference ID 43774065 or the Opexa Therapeutics Earnings Call.
A live webcast of the call can also be accessed
here or via the webcast link on the Investor Relations page of Opexa's website (
There will be a brief Question & Answer session following management commentary.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from a patient’s peripheral blood, expanded ex vivo, and reintroduced into the patient via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.
While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.